Galapagos NV : Galapagos receives €2.5 million IWT grant for IBD research

  Galapagos NV : Galapagos receives €2.5 million IWT grant for IBD research

Mechelen, Belgium; 30 January 2013  - Galapagos NV (Euronext: GLPG)  announced 
today that it has been  awarded a €2.5 million  grant from the Flemish  agency 
for Innovation by Science and Technology (IWT) for inflammatory bowel  disease 
(IBD) research  and development.  The goal  of this  2.5-year project  is  to 
identify new therapeutic compounds for future treatment of IBD patients. 

Inflammatory bowel disease  (IBD) is a  chronic, uncontrolled inflammation  of 
the intestinal mucosa. Crohn's disease  (CD) and ulcerative colitis (UC)  are 
the two main types  of IBD; both diseases  have an autoimmune component.  The 
introduction  of  anti-TNF  alpaantibodies  has  changed  the  treatment   of 
refractory patients, but only one third of the patients will achieve long-term
remission. As such, the medical need in this patient segment is very high.

The general purpose of the IWT-funded program is to gain better insight in the
roles of GPR43  and two  undisclosed targets  in the  pathobiology of  chronic 
inflammatory disorders,  in  order  to  understand  their  therapeutic  value. 
Galapagos will collaborate in this  project with Professor Dr Paul  Rutgeerts 
and Professor Dr Séverine Vermeire from the Catholic University of Leuven, and
the research group of Professor Dr Martine De Vos at Ghent University.

Galapagos has been working in the anti-inflammatory field for a long time, and
has several projects  with IBD  as potential indication.  The first  compound 
that will be tested in IBD patients is GLPG0974, an inhibitor of target  GPR43 
(also known as FFA2). This target is one of the three whose role in IBD  will 
be investigated in this IWT-funded project. Galapagos has recently  completed 
a second Phase I clinical study with GLPG0974, and results are expected to  be 
reported later this quarter. In April Galapagos will start a Proof of Concept
study with GLPG0974 in UC.

"After RA, IBD  is the second  autoimmune disease focus  for Galapagos.  With 
this grant we will get  a better understanding of the  cause of IBD, and  this 
will contribute to the search for better medicines," said Piet Wigerinck,  CSO 
of Galapagos. "The knowledge that will  come from this research will  provide 
more insight into the potential of our programs for use in this indication."

About IBD
Inflammatory bowel diseases (IBD) are disorders of multi-factorial cause  that 
present as  a  multitude  of  phenotypes,  clinical  behaviors  and  severity. 
Crohn's disease (CD) and  ulcerative colitis (UC) are  the two main types  of 
IBD. The peak age of onset is 15 to 30 years old, with a second, smaller peak
occurring in  individuals aged  50 to  70,  with the  prevalence rate  of  IBD 
reaching up to 396/100,000 persons.
The hallmark of  IBD is  chronic uncontrolled inflammation  of the  intestinal 
mucosa, involving a pathological response  in both innate and adaptive  immune 
system. The pathogenesis  is an interplay  of factors as  diverse as  genetic 
susceptibility, the  external environment,  infectious agents,  the  commensal 
enteric microbiota,  and (mucosal)  immune system  dysfunction. However,  the 
current understanding of the pathogenesis remains limited. The characteristic
inflammatory response begins with infiltration of neutrophils and macrophages,
which  release  chemokines  and  cytokines.  These  in  turn  exacerbate  the 
dysfunctional immune response and activate  cellular and humoral responses  in 
the gut mucosa.

About Galapagos
Galapagos  (Euronext:  GLPG;  OTC:  GLPYY)   is  a  mid-size  clinical   stage 
biotechnology company specialized  in the discovery  and development of  small 
molecule and antibody therapies with  a novel mode-of-action. The Company  is 
progressing four  clinical, six  pre-clinical, and  30 discovery  programs  in 
cystic fibrosis,  inflammation,  antibiotics,  metabolic  disease,  and  other 
Its lead  program is  GLPG0634, an  orally-available, selective  inhibitor  of 
JAK1,  for  the  treatment  of  rheumatoid  arthritis  and  potentially  other 
inflammatory diseases.  In two  four-week Phase  2 studies,  GLPG0634  showed 
improvement in the  signs and symptoms  of rheumatoid arthritis  and a  unique 
safety profile. A 6-month Phase  2b study is expected  to start Q2 2013  with 
topline data expected  in Q4 2014.  AbbVie and Galapagos  signed a  worldwide 
license agreement whereby AbbVie will  be responsible for further  development 
and commercialization after Phase 2b. Galapagos is also progressing two other
clinical  development  programs  with  clinical  readouts  expected  in  2013: 
GLPG0187, a novel integrin receptor antagonist in development for  metastasis, 
is in a  Phase 1b patient  study; GLPG0974  is the first  inhibitor of  GPR43, 
which is currently often referred  to as FFA2. It  will be evaluated for  the 
treatment of IBD. This program is in Phase  1 and a Proof of Concept Phase  2 
study will start in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over  800 employees  and operates facilities  in five  countries, 
with global headquarters in Mechelen, Belgium. Further information about  the 
company and its drug development programs can be found online at:


Galapagos NV
Dr Piet Wigerinck, Chief Scientific Officer
Tel. +32 477 627103

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or

Galapagos receives €2.5 million IWT grant for IBD research


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Galapagos NV via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.